Sage Therapeutics (SAGE)
(Delayed Data from NSDQ)
$11.90 USD
-0.44 (-3.57%)
Updated May 10, 2024 04:00 PM ET
After-Market: $11.89 -0.01 (-0.08%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth D Momentum F VGM
Sage Therapeutics, Inc. (SAGE) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$22.24 | $70.00 | $14.00 | 80.23% |
Price Target
Based on short-term price targets offered by 17 analysts, the average price target for Sage Therapeutics, Inc. comes to $22.24. The forecasts range from a low of $14.00 to a high of $70.00. The average price target represents an increase of 80.23% from the last closing price of $12.34.
Analyst Price Targets (17)
Broker Rating
Sage Therapeutics, Inc. currently has an average brokerage recommendation (ABR) of 2.67 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 21 brokerage firms. The current ABR compares to an ABR of 2.62 a month ago based on 21 recommendations.
Of the 21 recommendations deriving the current ABR, four are Strong Buy, representing 19.05% of all recommendations. A month ago, Strong Buy represented 19.05%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 4 | 4 | 4 | 4 | 4 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 16 | 16 | 17 | 18 | 18 |
Sell | 1 | 1 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 2.67 | 2.67 | 2.62 | 2.64 | 2.64 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/26/2024 | Truist Securities | Joon Lee | Hold | Hold |
4/26/2024 | Canaccord Genuity | Sumant Kulkarni | Hold | Hold |
4/26/2024 | Mizuho SecuritiesUSA | Uy D Ear | Hold | Hold |
4/25/2024 | Not Identified | Not Identified | Hold | Hold |
4/25/2024 | William Blair | Timothy F Lugo | Hold | Hold |
4/18/2024 | Scotiabank | George Farmer | Strong Buy | Strong Buy |
4/18/2024 | Needham & Company | Ami Fadia | Hold | Hold |
4/17/2024 | H.C. Wainwright & Co. | Douglas Tsao | Hold | Hold |
4/17/2024 | Wedbush Securities | Laura Chico | Hold | Hold |
12/1/2023 | Guggenheim Securities | Yatin Suneja | Hold | Hold |
11/7/2023 | SVB Securities | Marc Goodman | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.67 |
ABR (Last week) | 2.67 |
# of Recs in ABR | 21 |
Average Target Price | $22.24 |
LT Growth Rate | 21.90% |
Industry | Medical - Drugs |
Industry Rank by ABR | 99 of 252 |
Current Quarter EPS Est: | -1.69 |